Sano delivers 5x faster recruitment for top precision medicine organisations
80% of clinical trials miss their enrollment deadlines. Sano’s direct-to-patient omnichannel approach helps you hit your recruitment targets on time and on budget.
Sano delivers 5x faster recruitment for top precision medicine organisations
80% of clinical trials miss their enrollment deadlines. Sano’s direct-to-patient omnichannel approach helps you hit your recruitment targets on time and on budget.
“We were finding it challenging to engage a difficult patient population. Sano Genetics provided comprehensive recruitment services and delivered in a fraction of the time. We were delighted with the result.”
Billy Boyle, CEO at Owlstone Medical
How the Sano platform enables accelerated recruitment
Single platform, multichannel recruitment strategy
Sano identifies and engages the right patients through: • Genetic databases • AI digital medical record analysis • Patient organisations • Digital advertisements • Healthcare providers
Genetic testing for precision medicine research
Sano integrates genetics into clinical trial recruitment, offering non-invasive at-home DNA tests to determine a patients' eligibility. In addition to convenience for patients, benefits of this approach include reduced site burden, improved referral quality, and increased randomisation rates.
Detailed forecasting and reporting
Sano enables ongoing optimisation and strategic decision making through comprehensive reporting across all recruitment channels. Targeting can be updated as appropriate based on the blend of patients needed, site locations, site capacity, and more.
Doubling the industry benchmark for Genetic Parkinson’s Patient Recruitment
An innovative biotech company approached Sano to identify and screen Parkinson's Disease patients with LRRK2:G2019S mutation in the USA and Europe. Through its extensive partner network, direct-to-patient recruitment channels, and at-home DNA testing, Sano identified eligible patients at a rate 2x the industry benchmark. This led to an expansion to other regions and a 55% cost reduction compared to DNA testing through site visits.
Greater success rate of LRRK2:G2019S patients recruited than industry benchmark.
Cost saved using at-home DNA testing service vs site visit.
Program expansion into new geographies.
Doubling the industry benchmark for Genetic Parkinson’s Patient Recruitment
An innovative biotech company approached Sano to identify and screen Parkinson's Disease patients with LRRK2:G2019S mutation in the USA and Europe. Through its extensive partner network, direct-to-patient recruitment channels, and at-home DNA testing, Sano identified eligible patients at a rate 2x the industry benchmark. This led to an expansion to other regions and a 55% cost reduction compared to DNA testing through site visits.
